Back to portfolio

Azitra, Inc.

Harnessing the microbiome to treat skin disease

Azitra was founded in 2014 based on the scientific work or Travis Whitfill and collaborators at Yale University and the Jackson Laboratory. The company is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases. The Company’s technology platform is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis that are being genetically engineered as therapies to treat eczema, ichthyosis vulgaris, inflammatory skin, irritated skin and orphan skin diseases including Netherton syndrome. These types of products, known as Live Biotherapeutic Products (LBPs), are cost-effective topical applications with the potential to solve skin disease challenges and avoid systemic therapy.